Genetic testing in screening patients with lung cancer that has been or will be removed by surgery.

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Studying the genes in a patient's tumor cells may help determine the best treatment for patients that have certain genetic changes."
Age:
18 to 100 years old
Gender:
Any
Healthy Volunteers:
No
Keywords:
lung cancer
Type:
Other study
Investigator:
Description
This study looks at genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
This study requires
Please contact for details
Who can participate?
Inclusion Criteria:

- PATIENT PRE-REGISTRATION ELIGIBILITY CRITERIA:

- For pre-surgical patients

- Suspected diagnosis of resectable non-small cell lung cancer; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 institutional review board (IRB) approved

- Suspected clinical stage of IIIA, II or large IB (defined as size >= 4cm)

- For post-surgical patients

- Completely resected non-small cell lung cancer; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 IRB approved

- Pathologic stage IIIA, II or IB (defined as size >= 4 cm)

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer

- No prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas; a secondary primary lung cancer is considered a concurrent malignancy and would make a patient ineligible for A151216

- No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4

- No patients known to be pregnant or lactating

- Patients who have had local genotyping are eligible, regardless of the local result

- No patients with recurrence of lung cancer after prior resection

- Note: Post-surgical patients should proceed to registration immediately following preregistration

- PATIENT REGISTRATION ELIGIBILITY CRITERIA:

- Completely resected NSCLC; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 IRB approved

- Pathologic stage IIIA, II, or large IB (defined as size >= 4 cm)

- Tissue available for the required analyses

- In order to allow for time for central genotyping and eligibility for the ALCHEMIST treatment trial, patients must register within the following eligibility windows, depending on the adjuvant treatment approach:

- If no adjuvant therapy, register patient within 75 days following surgery

- If adjuvant chemotherapy only, register patient within 225 days following surgery

- If adjuvant chemotherapy and radiation, register patient within 285 days following surgery
Resources
Schedule
Study duration and period
Please contact for details
Recruitment period
From Feb. 20, 2015
Location
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Research Topic
Conditions:
  • Large Cell Lung Carcinoma
  • Lung Adenocarcinoma
  • Stage IB Non-Small Cell Lung Carcinoma
  • Stage IB Squamous Cell Lung Carcinoma
  • Stage IIA Non-Small Cell Lung Carcinoma
  • Stage IIA Squamous Cell Lung Carcinoma
  • Stage IIB Non-Small Cell Lung Carcinoma
  • Stage IIB Squamous Cell Lung Carcinoma
  • Stage IIIA Non-Small Cell Lung Cancer
  • Stage IIIA Squamous Cell Lung Carcinoma

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview